UNASSIGNED: We searched PubMed, MEDLINE, EMBASE, and the Cochrane Library for randomized controlled trials and observational studies published until August 2023. We included studies involving: patients with rhegmatogenous retinal detachment associated with choroidal detachment with proliferative vitreoretinopathy; an experimental group that was not administered steroids and a control group that was administered steroids; and assessment of visual acuity, retinal reattachment rate, and complications. The heterogeneity, publication bias, and sensitivity analysis were performed to ensure the statistical power and reliability of the analysis.
UNASSIGNED: Two randomized controlled trials and four case-control studies involving 490 eyes were included in the meta-analysis. There were no significant differences in the primary and final retinal reattachment rates after surgery between the steroid and non-steroid groups (primary retinal reattachment rate: odds ratio = 1.01, 95% confidence interval = 0.63-1.63, p = .41; final retinal reattachment rate: odds ratio = 0.82, 95% confidence interval = 0.43-1.59, p = .33). There was no statistically significant difference in postoperative visual acuity improvement between the two groups (odds ratio = 1.19, confidence interval = 0.63-2.25, p = .69). In addition, subgroup analyses of different types of steroids showed that systemic and local administration of steroids had similar results for retinal reattachment rate and visual acuity improvement.
UNASSIGNED: Patients with rhegmatogenous retinal detachment associated with choroidal detachment who did not receive preoperative steroids achieved the same effect as patients with rhegmatogenous retinal detachment associated with choroidal detachment who did receive preoperative steroids in terms of retinal reattachment rate and visual acuity. It is recommended that patients with rhegmatogenous retinal detachment associated with choroidal detachment undergo surgery as promptly as possible.
■我们搜索了PubMed,MEDLINE,EMBASE,和Cochrane图书馆的随机对照试验和观察性研究发表至2023年8月。我们纳入的研究涉及:与脉络膜脱离相关的血源性视网膜脱离伴增生性玻璃体视网膜病变的患者;未给予类固醇的实验组和给予类固醇的对照组;和视力评估,视网膜复位率,和并发症。异质性,出版偏见,进行了敏感性分析,以确保分析的统计能力和可靠性。
■两项涉及490只眼的随机对照试验和四项病例对照研究纳入荟萃分析。类固醇和非类固醇组术后的原发性和最终视网膜复位率没有显着差异(原发性视网膜复位率:比值比=1.01,95%置信区间=0.63-1.63,p=.41;最终视网膜复位率:比值比=0.82,95%置信区间=0.43-1.59,p=.33)。两组术后视力改善无统计学差异(比值比=1.19,置信区间=0.63-2.25,p=0.69)。此外,对不同类型类固醇的亚组分析显示,全身和局部给予类固醇在视网膜复位率和视力改善方面具有相似的结果.
■术前未接受类固醇治疗的脉络膜脱离相关的孔源性视网膜脱离患者,在视网膜复位率和视力方面,与术前接受类固醇治疗的脉络膜脱离相关的孔源性视网膜脱离患者的效果相同。建议与脉络膜脱离相关的孔源性视网膜脱离患者尽快接受手术。